In vivo studies in pancreatic ductal adenocarcinoma (PDAC) further validate the oncogenic potential of MED30, as its overexpression promotes tumor growth and can be attenuated by knockdown of MYC. The gene discussed is MYC; the disease is pancreatic ductal adenocarcinoma.